Results 81 to 90 of about 6,415 (210)

Antifungal activity and killing kinetics of anidulafungin, caspofungin and amphotericin B against Candida auris

, 2019
DigitalBackground: Candida auris is an emerging MDR pathogen. It shows reduced susceptibility to azole drugs and, in some strains, high amphotericin B MICs have been described. For these reasons, echinocandins were proposed as first-line treatment for C.
Morales López, Soraya, Gamarra, Soledad, Theill, Laura, Macedo, Daiana, Dudiuk, Catiana, Leonardelli, Florencia, Rodríguez, José-Yesid, Berrio, Indira, Salcedo, Soraya, Marín, Adriana, Garcia Effron, Guillermo   +10 more
core   +1 more source

Neglected Mycoses in Brazil: A Population‐Based Study of Mortality and In‐Hospital Mortality Over 25 Years

Mycoses, Volume 69, Issue 2, February 2026.
ABSTRACT Objective To describe the epidemiology, associated factors, spatial distribution, and temporal trends of mortality and in‐hospital mortality related to systemic mycoses in Brazil, 2000–2024. Methods This is a nationwide ecological study combining temporal and spatial analyses using death certificates (DC; underlying and/or associated causes ...
Anderson Fuentes Ferreira, Jorg Heukelbach, Eliana Amorim de Souza, Maria Aparecida Shikanai‐Yasuda, Lisandra Serra Damasceno, Fernanda Dockhorn Costa, Terezinha do Menino Jesus Silva Leitão, Helia Kawa, Alberto Novaes Ramos Jr.   +8 more
wiley   +1 more source

[Anidulafungin].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2008
Anidulafungin is a new echinocandin antifungal agent recently approved in Spain by the Spanish Drug Agency. As other echinocandins, it inhibits a selective target, 1,3- beta-D-glucan synthesis, a major structural component of the fungal cell wall which is not present in mammalian cells, this avoiding toxicity problems.
M, Gobernado, E, Cantón
openaire   +1 more source

Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials [PDF]

, 2017
Contains fulltext : 177342.pdf (Publisher’s version ) (Open Access)Objectives: To evaluate the efficacy of anidulafungin for the treatment of candidaemia and invasive candidiasis in a large dataset, including patients with deep-seated ...
José-Artur Paiva, Kullberg, B.J., Yan, J.L., Jean Li Yan, Bart Jan Kullberg, Conte, U., Schlamm, H., Vasquez, J., Herbrecht, R., Paiva, J.A., Aram, J., Garbino, J., Maria Rita Capparella, Marcio Nucci, Swanson, R., Mootsikapun, P., José Vasquez, Piroon Mootsikapun, Jalal Aram, Jorge Garbino, Raoul Herbrecht, Nucci, M., Haran Schlamm, Robert Swanson, Umberto Conte, Capparella, M.R.   +25 more
core   +1 more source

Early phenotypic detection of fluconazole- and anidulafungin-resistant Candida glabrata isolates

, 2022
BACKGROUND: Increased fluconazole and echinocandin resistance in Candida glabrata requires prompt detection in routine settings. A phenotypic test based on the EUCAST E.DEF 7.3.2 protocol was developed for the detection of fluconazole- and anidulafungin ...
Meletiadis, Joseph, Georgiou, Panagiota Christina, Arendrup, Maiken Cavling   +2 more
core   +1 more source

Filter Adsorption of Anidulafungin to a Polysulfone-Based Hemofilter During CVVHD In Vitro

, 2017
Candidemia is frequent in critically ill patients, especially in combination with an acute kidney injury (AKI). Echinocandins generally are recommended for therapy of such infections.
Michael Gruber, Bernhard M. Graf, Ittner, Karl-Peter, Gabriel Roth, Peter Kolbinger, Kolbinger, Peter, Karl-Peter Ittner, Gruber, Michael, Roth, Gabriel, Graf, Bernhard M.   +9 more
core   +1 more source

Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey

, 2017
Anidulafungin has been shown to be non-inferior to, and possibly more efficacious, than fluconazole in treating patients with invasive candidiasis (IC). This study aimed to determine the cost-effectiveness of anidulafungin vs fluconazole for treatment of
Turner, Stuart J., Esin Senol, Stuart J. Turner, Chin Fen Neoh, Kong, David C. M., Senol, Esin, Ates Kara, KARA, ATEŞ, David C. M. Kong, DİNLEYİCİ, ENER ÇAĞRI, Ener Cagri Dinleyici, Neoh, Chin Fen   +11 more
core   +1 more source

Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole resistant invasive aspergillosis.

, 2013
Contains fulltext : 118362.pdf (Publisher’s version ) (Open Access)OBJECTIVES: Azole resistance is an emerging problem in the treatment of Aspergillus fumigatus infections.
Melchers, W.J.G., Seyedmousav, S., Mouton †, J.W., Mouton, J.W., Bruggemann, R.J.M., Verweij, P.E.   +5 more
core   +1 more source

Anidulafungin dosing in critically ill patients with continuous venovenous haemodifiltration

Background: Anidulafungin is indicated as a first-line treatment for invasive candidiasis in critically ill patients. In the intensive care unit, sepsis is the main cause of acute renal failure, and treatment with continuous renal replacement therapy ...
Aguilar Aguilar, Gerardo, Badenes-Quiles, Rafael, Belda Nacher, Francisco Javier, Navarro Ortega, David   +3 more
core   +1 more source

Anidulafungin for Neonatal Hematogenous Candida Meningoencephalitis: Identification of Candidate Regimens for Humans Using a Translational Pharmacological Approach

, 2012
Hematogenous Candida meningoencephalitis (HCME) is a serious infection in premature neonates. Anidulafungin is an echinocandin antifungal agent with potent activity against Candida spp., but its efficacy ...
Peter A. Warn, William W. Hope, Gregson, Lea, Susan Howard, Goodwin, Joanne, Joanne Goodwin, Michael Cohen-Wolkowiez, Cohen-Wolkowiez, Michael, Ruta Petraitiene, Daniel K. Benjamin, Vidmantas Petraitis, Petraitis, Vidmantas, Howard, Susan, Thomas J. Walsh, Warn, Peter A, Timothy W. Felton, Livermore, Joanne, Andrew Sharp, Lea Gregson, Felton, Timothy W; id_orcid, Petraitiene, Ruta, Joanne Livermore, Sharp, Andrew   +22 more
core   +1 more source